Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LV 009

Next Previous
Drug Profile

LV 009

Alternative Names: LV-009

Latest Information Update: 14 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PersonGen Biotherapeutics
  • Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Preclinical Autoimmune disorders

Most Recent Events

  • 31 Dec 2025 PersonGen Biotherapeutics plans to initiate a early phase I trial for Precursor B-cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater) (IV) (NCT07330895)
  • 12 Nov 2025 Preclinical trials in Autoimmune disorders in China (IV), prior to November 2025 (PersonGen BioTherapeutics pipeline, November 2025)
  • 29 Oct 2025 Clinical trials in Non-Hodgkin's lymphoma in China (IV) (PersonGen BioTherapeutics pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top